Scopio Labs

Scopio Labs develops digital microscopy platforms for cell morphology, combining full-field high-resolution imaging with AI-based decision support for hematology laboratories and hospitals. The platform uses computational photography: a low-resolution objective rapidly acquires images of a slide under varying illumination conditions, and algorithms then compute a sharp image at 100X-equivalent resolution across the full field of view. This is intended to remove the traditional trade-off between field of view and resolution, so that practitioners can view an entire blood smear in context — including regions such as the feathered edge — and zoom in on any cell at high resolution, without returning to a manual microscope.

The company positions its systems as an alternative to manual microscopy and to semi-digital solutions that capture only single-cell snapshots from automatically selected analysis areas. Product scope spans peripheral blood smear analysis, digital bone marrow applications, and a Complete Blood Morphology (CBM) analyzer unveiled in 2025 that the company describes as fully automating blood morphology. Software capabilities include remote access to scans, allowing offsite clinicians, consulting hematopathologists and collaborators to review and consult on the same full-slide images, plus DICOM integration and analysis management features in later releases.

Founding story

Co-founders Itai Hayut and Erez Na'aman met at university, where Hayut studied physics at the Hebrew University; Hayut also attended a summer program at Singularity University in Silicon Valley. Working in hospitals, they observed practitioners counting cells manually under traditional analog microscopes, with no easy way to share microscopic data, collaborate with specialists or apply AI-based image analysis. They initially intended to buy a slide scanner and layer AI tools on top, but found no scanner capable of the required imaging, so building the scanner became the company's first task.

Business model

Scopio Labs sells imaging and analysis platforms (hardware scanners plus embedded AI software) to clinical laboratories and hospitals, supported by sales, marketing and customer support organizations that the company said it would scale following its 2024 Series D.

Traction

The company reported total fundraising of $130 million as of its July 2024 Series D, and cited commercial expansion, market penetration and global footprint growth as uses of that capital.

Latest developments

In July 2025 Scopio unveiled its Complete Blood Morphology (CBM) analyzer, described as an AI-powered solution that fully automates blood morphology. In February 2026 the company announced IVDR certification from BSI for its AI-powered Full-Field digital morphology platforms, and in April 2026 it announced EU IVDR certification for its Full-Field digital bone marrow application alongside a software release adding DICOM integration and advanced analysis management.